Copyright 2009 Medical News Today Latest Gout News From Medical News Today. http://www.medicalnewstoday.com/sections/gout/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Mon, 26 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/168661.php http://www.medicalnewstoday.com/articles/168661.php PHILADELPHIA - New data show that low-dose colchicine (ColcrysTM) rapidly controls acute gout flares. The results, which were presented at the 2009 Annual Scientific Meeting of the American College of Rheumatology, are drawn from a secondary analysis of the phase III Acute Gout Flare Receiving Colchicine Evaluation (AGREE) trial. Gout Wed, 21 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/168063.php http://www.medicalnewstoday.com/articles/168063.php Ardea Biosciences, Inc. (Nasdaq: RDEA) announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. Gout Wed, 21 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/168028.php http://www.medicalnewstoday.com/articles/168028.php Additional analysis showed that reduction and long-term maintenance of normal serum urate levels also reduced risk of future gout flares Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to Gout Tue, 20 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/167896.php http://www.medicalnewstoday.com/articles/167896.php URL Pharma, Inc., announced data from a pivotal Phase III study demonstrating that Colcrys(TM) (colchicine, USP), a low-dose colchicine, reduced the pain of gout flares within a 24-hour period as effectively as high-dose colchicine with a side effect profile statistically indistinguishable from placebo. These data and two other Colcrys studies were presented this week at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting in Philadelphia. Gout Tue, 20 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/167904.php http://www.medicalnewstoday.com/articles/167904.php URL Pharma, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Colcrys(TM) (colchicine, USP) for the prophylaxis (prevention) of gout flares. Colcrys was first approved by the FDA on July 30, 2009 for the treatment of acute gout flares when taken at the first sign of a flare. Colcrys is an oral, branded form of colchicine that has been formulated for optimal efficacy and tolerability. Gout Mon, 19 Oct 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/167828.php http://www.medicalnewstoday.com/articles/167828.php Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to Gout Tue, 13 Oct 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/167173.php http://www.medicalnewstoday.com/articles/167173.php Parkinson disease progresses more slowly in patients who have higher levels of urate, a chemical that at very high level is associated with gout, scientists have found. While it's unknown whether the high levels actually somehow protect patients or simply serve as a marker of protection, the finding supports the idea that patients and doctors may one day be able to better predict the course of the illness. Parkinson's Disease Tue, 29 Sep 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/165463.php http://www.medicalnewstoday.com/articles/165463.php BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it is initiating a Phase 2 study of BCX4208 for the treatment of gout. The primary objective of BioCryst's Phase 2 study is to determine the effect of different doses of orally administered BCX4208 on serum uric acid levels in patients with gout. The gout trial is expected to enroll up to 120 subjects. "Over the last few decades gout has markedly increased in incidence and prevalence, both in the U.S. and elsewhere. Gout Mon, 28 Sep 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/165429.php http://www.medicalnewstoday.com/articles/165429.php EnzymeRx, LLC a clinical-stage biotechnology company, announced that its Investigational New Drug (IND) application for Uricase-PEG 20, filed with the U.S. Food and Drug Administration (FDA) last month, has become effective. EnzymeRx filed this IND for intravenous Uricase-PEG 20 in the management of elevated uric acid levels associated with tumor lysis syndrome. Gout Tue, 04 Aug 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/159658.php http://www.medicalnewstoday.com/articles/159658.php Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) stating that the FDA can not at this time approve the Company's Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Gout Sun, 02 Aug 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/159473.php http://www.medicalnewstoday.com/articles/159473.php The U.S. Food and Drug Administration has approved Colcrys to treat acute flairs in patients with gout, a recurrent and painful form of arthritis, and patients with familial Mediterranean fever (FMF), an inherited inflammatory disorder. The medication's active ingredient is colchicine, a complex compound derived from the dried seeds of a plant known as the autumn crocus or meadow saffron (Colchicum autumnale). Gout Wed, 22 Jul 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/158309.php http://www.medicalnewstoday.com/articles/158309.php Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced that it has initiated a Phase 2b clinical trial of RDEA594, its lead product candidate in development for the management of hyperuricemia and gout. The Company also announced the selection of RDEA684, a next-generation URAT1 inhibitor, as a development candidate for the same indication. Gout Sat, 20 Jun 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/154718.php http://www.medicalnewstoday.com/articles/154718.php Having partnered last year with an international team that surveyed the genomes of 12,000 individuals to find a genetic cause for gout, Johns Hopkins scientists now have shown that the malfunctioning gene they helped uncover can lead to high concentrations of blood urate that forms crystals in joint tissue, causing inflammation and pain the hallmark of this disease. Gout Fri, 19 Jun 2009 07:00:00 PST http://www.medicalnewstoday.com/articles/154658.php http://www.medicalnewstoday.com/articles/154658.php Having partnered last year with an international team that surveyed the genomes of 12,000 individuals to find a genetic cause for gout, Johns Hopkins scientists now have shown that the malfunctioning gene they helped uncover can lead to high concentrations of blood urate that forms crystals in joint tissue, causing inflammation and pain - the hallmark of this disease. Gout Wed, 17 Jun 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/154203.php http://www.medicalnewstoday.com/articles/154203.php Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a vote of 14 to 1 that KRYSTEXXA(TM) (pegloticase), a biologic PEGylated uricase enzyme, be granted marketing approval by the FDA for the treatment of refractory chronic gout. Gout Sun, 14 Jun 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/153784.php http://www.medicalnewstoday.com/articles/153784.php Ardea Biosciences, Inc. (Nasdaq:RDEA) announced positive interim results from an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as additional positive results from completed Phase 1 studies of RDEA594 in normal, healthy volunteers. Gout Sat, 06 Jun 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/152679.php http://www.medicalnewstoday.com/articles/152679.php Researchers at the University of California, San Diego School of Medicine have developed the first mouse model for auto-inflammatory diseases, disorders that involve the over-activation of the body's innate, primitive immune system. Their study, published early on-line in Cell Immunity on June 4, suggests that the innate - not adaptive - immune system drives auto-inflammatory diseases. Immune System / Vaccines Fri, 05 Jun 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/152620.php http://www.medicalnewstoday.com/articles/152620.php The most reliable method of diagnosing gout is to aspirate the joint in order to obtain fluid to verify the presence of monosodiumurate crystals (uric acid). Up to now, computed tomography (CT) has played a limited role in the evaluation of gout, since conventional CT systems cannot reliably verify deposits of uric acid. Gout Mon, 01 Jun 2009 15:00:00 PST http://www.medicalnewstoday.com/articles/152120.php http://www.medicalnewstoday.com/articles/152120.php Bursitis happens when the bursa is inflamed. The burse acts as a cushion between bones, tendons, joints and muscles - bursae are fluid-filled sacs (the plural of bursa is bursae). People with bursitis will feel pain at the site of inflammation. The medical word "bursa" comes from the Latin bursa, meaning a purse, which is what a bursa resembles. According to Medilexicon's Pain / Anesthetics Thu, 28 May 2009 07:00:00 PST http://www.medicalnewstoday.com/articles/151742.php http://www.medicalnewstoday.com/articles/151742.php The most reliable method of diagnosing gout is to aspirate the joint in order to obtain fluid to verify the presence of monosodium urate crystals (uric acid). Up to now, computed tomography (CT) has played a limited role in the evaluation of gout, since conventional CT systems cannot reliably verify deposits of uric acid. Gout Sat, 23 May 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/151178.php http://www.medicalnewstoday.com/articles/151178.php The Gout & Uric Acid Education Society announced that new survey results reveal alarming gaps in the public's awareness of gout, a painful and potentially debilitating form of arthritis that affects three to five million Americans. In a survey of more than 2,000 Americans, 65% of adults admitted to being "not at all knowledgeable" about gout and just over 70% did not know that gout is a form of arthritis. In fact, gout is the most common form of inflammatory arthritis among adults. Gout Thu, 02 Apr 2009 07:00:00 PST http://www.medicalnewstoday.com/articles/144827.php http://www.medicalnewstoday.com/articles/144827.php The word gout comes from Latin gutta and old French gote meaning "a drop". Several hundred years ago gout was thought to be caused by drops of viscous humors that seeped from blood into the joints. In fact, this supposition was not that far from the truth. When a patient experiences the symptoms of a gout attack uric acid has been accumulating in his blood, and uric acid deposits have been forming in the joints. Gout Mon, 09 Mar 2009 13:00:00 PST http://www.medicalnewstoday.com/articles/141562.php http://www.medicalnewstoday.com/articles/141562.php Men with higher vitamin C intake appear less likely to develop gout, a painful type of arthritis, according to a report in the March 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. "Gout is the most common type of inflammatory arthritis in men," the authors write as background information in the article. "Epidemiologic studies suggest that the overall disease burden of gout is substantial and growing. Gout Mon, 16 Feb 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/139130.php http://www.medicalnewstoday.com/articles/139130.php The US Food and Drug Administration has given marketing approval to a new drug that lowers levels of uric acid in the blood of patients with gout: the current treatment for the condition was developed over 40 years ago. The new drug is called ULORIC (generic name febuxostat) and Takeda Pharmaceuticals North America is the sole developer and marketer of the product in the US. Gout Mon, 16 Feb 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/139133.php http://www.medicalnewstoday.com/articles/139133.php Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced today that the United States Food and Drug Administration (FDA) has approved ULORIC(R) (febuxostat) 40 mg and 80 mg for the chronic management of hyperuricemia in patients with gout. Gout